{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T10:27:38Z","timestamp":1648808858223},"reference-count":25,"publisher":"Bentham Science Publishers Ltd.","issue":"3","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CCP"],"published-print":{"date-parts":[[2019,12,31]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Cotrimoxazole is the main antibiotic used in primary prophylaxis for\nopportunistic infections in advanced HIV infection. This drug can inhibit one of the metabolic\npathways of atazanavir (ATV), such as the cytochromes P450 (CYP) 2C8\/2C9 and could interfere\nwith its safety and efficacy.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>We studied the drug-drug interaction (DDI) between cotrimoxazole and ATV by using\ntherapeutic drug monitoring (TDM) and pharmacovigilance (PV) approaches.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>We compared a group of patients treated with cotrimoxazole and receiving an ATV-based\nregimen to controls. This historical cohort analysis used data from Dat\u2019AIDS in HIV-infected patients\nwho had at least two lowest plasma concentrations (C-trough) of ATV during their outpatient\nfollow-up. Likewise, we used the international pharmacovigilance data from VigiBase to evaluate\nthe notifications of hyperbilirubinemia reported with ATV.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>In the TDM analysis, the two groups of patients (treated with cotrimoxazole and controls)\nwere almost homogeneous concerning the main baseline features. After at least six months of ATVbased\nregimen, there was no significant difference in the safety threshold of the ATV C-trough\n[with an adjusted odds ratio (aOR) of 1.4 (95% CI: 0.5 - 4.4)] compared to controls. We observed\nsimilar results with the efficacy thresholds of ATV C-trough. Regarding the PV analysis, there was\nno difference in hyperbilirubinemia occurring with ATV when cotrimoxazole was concomitant,\nwith an adjusted reporting odds ratio (aROR) of 0.9 (95% CI: 0.6 to 1.2).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>This study showed a relevant concomitant use between Cotrimoxazole and ATV based\non TDM and PV approaches.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1574884714666190405160612","type":"journal-article","created":{"date-parts":[[2019,4,9]],"date-time":"2019-04-09T10:30:04Z","timestamp":1554805804000},"page":"214-223","update-policy":"http:\/\/dx.doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Concomitant Use of Cotrimoxazole and Atazanavir in HIV-infected Patients: A Therapeutic Drug Monitoring and Pharmacovigilance Based Dual Approach"],"prefix":"10.2174","volume":"14","author":[{"given":"Miantezila B.","family":"Joe","sequence":"first","affiliation":[{"name":"EA4065 Ecosyst\u00e8me Intestinal, Probiotique, Antibiotiques, Universit\u00e9 Paris Descartes SPC, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Landman","family":"Roland","sequence":"additional","affiliation":[{"name":"Service des Maladies Infectieuses et Tropicales, H\u00f4pital Bichat, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chouchana","family":"Laurent","sequence":"additional","affiliation":[{"name":"Centre R\u00e9gional de Pharmacovigilance, H\u00f4pital Cochin, Assistance publique-Hopitaux de Paris, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L\u00ea M.","family":"Patrick","sequence":"additional","affiliation":[{"name":"IAME, UMR 1137, Universit\u00e9 Paris Diderot, Sorbonne Paris Cit\u00e9 and INSERM, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Sawoo","sequence":"additional","affiliation":[{"name":"EA4065 Ecosyst\u00e8me Intestinal, Probiotique, Antibiotiques, Universit\u00e9 Paris Descartes SPC, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tona L.","family":"Gaston","sequence":"additional","affiliation":[{"name":"Unit\u00e9 de Pharmacologie Clinique, Universit\u00e9 de Kinshasa, Kinshasa, Congo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eto","family":"Bruno","sequence":"additional","affiliation":[{"name":"TBC TransCell-Lab, Facult\u00e9 de M\u00e9decine Xavier Bichat, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peytavin","family":"Gilles","sequence":"additional","affiliation":[{"name":"IAME, UMR 1137, Universit\u00e9 Paris Diderot, Sorbonne Paris Cit\u00e9 and INSERM, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pochart","family":"Philippe","sequence":"additional","affiliation":[{"name":"EA4065 Ecosyst\u00e8me Intestinal, Probiotique, Antibiotiques, Universit\u00e9 Paris Descartes SPC, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.8900","volume":"316","author":"G\u00fcnthard H.F.","year":"2016","unstructured":"G\u00fcnthard H.F.; Saag M.S.; Benson C.A.; Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 Recommendations of the International Antiviral Society-USA Panel. JAMA 2016,316(2)","journal-title":"JAMA"},{"key":"ref=2","author":"Roncier C.","unstructured":"Roncier C.; Rapport Morlat 2016: Des nouveaut\u00e9s dans la prise en charge des personnes vivant avec le VIH. 2016 [cit\u00e9 11 juill 2018]. Disponible sur: [Accessed July 11, 2018]"},{"key":"ref=3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0089943","volume":"9","author":"Dossou-Yovo F.","year":"2015","unstructured":"Dossou-Yovo F.; Mamadou G.; Soudy I.D.; Metronidazole or cotrimoxazole therapy is associated with a decrease in intestinal bioavailability of common antiretroviral drugs. PLoS One 2015,9(2)","journal-title":"PLoS One"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"213","DOI":"10.2515\/therapie\/2011032","volume":"66","author":"Solas C.","year":"2011","unstructured":"Solas C.; Muret P.; Groupe suivi therapeutique pharmacolo-gique de la societe francaise de pharmacologie et de thera-peutique. Therapie 2011,66(3),213-219","journal-title":"Therapie"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1592\/phco.24.17.1732.52347","volume":"24","author":"Busti A.J.","year":"2004","unstructured":"Busti A.J.; Hall R.G.; Margolis D.M.; Atazanavir for the treatment of human immunodeficiency virus infection. Pharmacotherapy 2004,24(12),1732-1747","journal-title":"Pharmacotherapy"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1124\/dmd.30.6.631","volume":"30","author":"Wen X.","year":"2002","unstructured":"Wen X.; Wang J-S.; Backman J.T.; Laitila J.; Neuvonen P.J.; Trimethoprim and sulfamethoxazole are selective inhibitors of CYP2C8 and CYP2C9, respectively. Drug Metab Dispos 2002,30(6),631-635","journal-title":"Drug Metab Dispos"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1089\/apc.2013.0009","volume":"27","author":"Laprise C.","year":"2013","unstructured":"Laprise C.; Baril J-G.; Dufresne S.; Trottier H.; Atazanavir and other determinants of hyperbilirubinemia in a cohort of 1150 HIV-positive patients: Results from 9 years of follow-up. AIDS Patient Care STDS 2013,27(7),378-386","journal-title":"AIDS Patient Care STDS"},{"key":"ref=8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0123670","volume":"10","author":"Gervasoni C.","year":"2015","unstructured":"Gervasoni C.; Meraviglia P.; Minisci D.; Metabolic and kidney disorders correlate with high atazanavir concentrations in HIV-infected patients: Is it time to revise atazanavir dosages? PLoS One 2015,10(4)","journal-title":"PLoS One"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/phar.1205","volume":"33","author":"Bertz RJ","unstructured":"Bertz RJ; Persson A; Chung E; Pharmacokinetics and pharmacodynamics of atazanavir-containing antiretroviral regimens, with or without ritonavir, in patients who are HIV-positive and treatment-na\u00efve. Pharmacother J Hum Pharmacol Drug Ther ,33(3),284-94","journal-title":"Pharmacother J Hum Pharmacol Drug Ther"},{"key":"ref=10","volume":"33","author":"Zhang D.","year":"2005","unstructured":"Zhang D.; Chando T.J.; Everett D.W.; Patten C.J.; Dehal S.S.; Hum-phreys W.G.; \n                        In vitro Inhibition of UDP glucuronosyl transferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. Drug Metab Dispos 2005,33(11)","journal-title":"Drug Metab Dispos"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1097\/QAD.0b013e328011d7c1","volume":"21","author":"Rodr\u00edguez-N\u00f3voa S.","year":"2007","unstructured":"Rodr\u00edguez-N\u00f3voa S.; Mart\u00edn-Carbonero L.; Barreiro P.; Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia. AIDS 2007,21(1),41-46","journal-title":"AIDS"},{"key":"ref=12","first-page":"299","volume":"32","author":"Pugliese P","year":"2003","unstructured":"Pugliese P; Cuzin L; Enel P;  NADIS 2000, development of an electronic medical record for patients infected by HIV, HBV and HCV. Presse Medicale Paris Fr 1983 22 f\u00e9vr 2003,32(7),299-303","journal-title":"Presse Medicale Paris Fr 1983 22 f\u00e9vr"},{"key":"ref=13","first-page":"46774","volume":"43","author":"Dellamonica P.","year":"2018","unstructured":"Dellamonica P.; Katlama C.; L\u00e9vy-Bachelot L.; Daures J-P.; Finkielsztejn L.; Abacavir (Ziagen) use between 2003 and 2008 in France according to the electronic medical record NADIS. M\u00e9decine Mal Infect 2018,43(11),46774","journal-title":"M\u00e9decine Mal Infect"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1002\/bmc.865","volume":"21","author":"Jung B.H.","year":"2007","unstructured":"Jung B.H.; Rezk N.L.; Bridges A.S.; Corbett A.H.; Kashuba A.D.M.; Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography-tandem mass spectrometry. Biomed Chromatogr 2007,21(10),1095-1104","journal-title":"Biomed Chromatogr"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1310\/0KX0-H9VH-99EE-5D0L","volume":"7","author":"Smith D.E.","year":"2006","unstructured":"Smith D.E.; Jeganathan S.; Ray J.; Atazanavir plasma concentrations vary significantly between patients and correlate with increased serum bilirubin concentrations. HIV Clin Trials 2006,7(1),34-38","journal-title":"HIV Clin Trials"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1093\/jac\/dkm298","volume":"60","author":"Cleijsen R.M.M.","year":"2007","unstructured":"Cleijsen R.M.M.; van de Ende M.E.; Kroon F.P.; Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice. J Antimicrob Chemother 2007,60(4),897-900","journal-title":"J Antimicrob Chemother"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1097\/FTD.0b013e3181cb479f","volume":"32","author":"Molt\u00f3 J.","year":"2010","unstructured":"Molt\u00f3 J.; Deig E.; Valle M.; Effect of nevirapine on the steady-state trough concentrations of atazanavir in HIV-infected patients receiving atazanavir\/ritonavir. Ther Drug Monit 2010,32(1),93-96","journal-title":"Ther Drug Monit"},{"key":"ref=18","unstructured":"VigiBase [Internet]. [cit\u00e9 2 ao\u00fbt 2018]. Disponible sur:  [Accessed August 2 2018]."},{"key":"ref=19","first-page":"290","volume":"58","author":"Hautekeete M.L.","year":"1995","unstructured":"Hautekeete M.L.; Hepatotoxicity of antibiotics. Acta Gastroenterol Belg 1995,58(3-4),290-296","journal-title":"Acta Gastroenterol Belg"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/clpt.1994.122","volume":"56","author":"Lee B.L.","year":"1994","unstructured":"Lee B.L.; Delahunty T.; Safrin S.; The hydroxylamine of sulfamethoxazole and adverse reactions in patients with acquired immunodeficiency syndrome. Clin Pharmacol Ther 1994,56(2),184-189","journal-title":"Clin Pharmacol Ther"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"291","DOI":"10.3109\/10715762.2013.770149","volume":"47","author":"Kobuchi S.","year":"2013","unstructured":"Kobuchi S.; Fukushima K.; Aoyama H.; Ito Y.; Sugioka N.; Takada K.; Effects of oxidative stress on the pharmacokinetics and hepatic metabolism of atazanavir in rats. Free Radic Res 2013,47(4),291-300","journal-title":"Free Radic Res"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1177\/00912709922011737","volume":"39","author":"Sturgill M.G.","year":"1999","unstructured":"Sturgill M.G.; Seibold J.R.; Boruchoff S.E.; Yeh K.C.; Haddix H.; Deutsch P.; Trimethoprim\/sulfamethoxazole does not affect the steady-state disposition of indinavir. J Clin Pharmacol 1999,39(10),1077-1084","journal-title":"J Clin Pharmacol"},{"key":"ref=23","first-page":"2303","volume":"40","author":"Ca\u00f1as E.","year":"2018","unstructured":"Ca\u00f1as E.; Pachon J.; Garcia-Pesquera F.; Absence of effect of trimethoprim-sulfamethoxazole on pharmacokinetics of zidovudine in patients infected with human immunodeficiency virus. Antimicrob Agents Chemother [https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC163089\/2018,40(1),2303","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1111\/j.1472-8206.2010.00905","volume":"26","author":"Cattaneo D.","year":"2018","unstructured":"Cattaneo D.; Meraviglia P.; Cozzi V.; Baldelli S.; Milani G.; Clementi E.; Atypical pharmacokinetics of atazanavir in an HIV-1-infected patient. Fundam Clin Pharmacol 2018,26(2),2046","journal-title":"Fundam Clin Pharmacol"},{"key":"ref=25","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/j.1472-8206.2011.01005.x","volume":"27","author":"Cattaneo D.","year":"2018","unstructured":"Cattaneo D.; Ripamonti D.; Baldelli S.; Cozzi V.; Fucile S.; Clementi E.; Limited sampling strategies for the estimation of atazanavir daily exposure in HIV-infected patients. Fundam Clin Pharmacol 2018,27(2),216-222","journal-title":"Fundam Clin Pharmacol"}],"container-title":["Current Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/171360","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T15:27:36Z","timestamp":1581089256000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/171360\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,31]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,12,31]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1574884714666190405160612","relation":{},"ISSN":["1574-8847"],"issn-type":[{"value":"1574-8847","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12,31]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-01-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-25","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}